Antiplatelet therapy in stroke prevention.
Ischemic stroke is a major cause of death and disability worldwide. Determination of the underlying stroke mechanism is critical for the optimization of treatment. The role of antiplatelet therapy in primary and secondary stroke prevention is of major significance. Antiplatelet agents predominantly in use are aspirin, clopidogrel, and combination regimens. Novel antiplatelet agents either in use or in advance clinical development seek an indication in the management of stroke patients; yet data are limited. The present review focuses on the optimization of antithrombotic therapy in the field of primary and secondary prevention of stroke, based on data obtained from randomized controlled trials and systemic reviews of the literature.
University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK.
Stavros
S
Apostolakis
Francisco
F
Marín
Gregory Y H
GY
Lip
D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011322:Primary Prevention; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention; D020521:Stroke / Q000517:prevention & control*; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin